Brief: Sanofi: FDA Extends Target Action Date For Sarclisa Subcutaneous Review
22/04/2026 06:23
April 22 (Reuters) - Sanofi SA SASY.PA: PRESS RELEASE: SANOFI PROVIDES UPDATE ON THE REGULATORY SUBMISSION FOR SARCLISA SUBCUTANEOUS IN THE US FDA EXTENDS TARGET ACTION DATE FOR SARCLISA SUBCUTANEOUS REVIEW BY UP TO THREE MONTHS REVISED FDA TARGET ACTION DATE FOR SARCLISA SUBCUTANEOUS IS JULY 23, 2026 Source text: ID:nGNX8s1cbG Further company coverage: SASY.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes